The stock of Caladrius Biosciences Inc (NASDAQ:CLBS) hit a new 52-week low and has $3.12 target or 12.00% below today’s $3.54 share price. The 9 months bearish chart indicates high risk for the $19.71M company. The 1-year low was reported on Nov, 2 by Barchart.com. If the $3.12 price target is reached, the company will be worth $2.37M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 37,754 shares traded hands or 25.75% up from the average. Caladrius Biosciences Inc (NASDAQ:CLBS) has declined 48.40% since March 31, 2016 and is downtrending. It has underperformed by 50.92% the S&P500.
Analysts await Caladrius Biosciences Inc (NASDAQ:CLBS) to report earnings on November, 3. They expect $-1.22 earnings per share, up 41.90% or $0.88 from last year’s $-2.1 per share. After $-1.33 actual earnings per share reported by Caladrius Biosciences Inc for the previous quarter, Wall Street now forecasts -8.27% EPS growth.
Caladrius Biosciences Inc (NASDAQ:CLBS) Ratings Coverage
Out of 4 analysts covering Caladrius Biosciences (NASDAQ:CLBS), 2 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 50% are positive. Caladrius Biosciences has been the topic of 7 analyst reports since August 7, 2015 according to StockzIntelligence Inc. Maxim Group maintained Caladrius Biosciences Inc (NASDAQ:CLBS) on Tuesday, December 22 with “Buy” rating. Benchmark downgraded the shares of CLBS in a report on Friday, August 7 to “” rating. The company was upgraded on Friday, April 29 by H.C. Wainwright. The company was downgraded on Friday, January 8 by H.C. Wainwright. The company was initiated on Tuesday, August 23 by Chardan Capital Markets. The firm has “Hold” rating by Maxim Group given on Thursday, January 7. On Friday, January 8 the stock rating was maintained by Benchmark with “Hold”.
According to Zacks Investment Research, “Caladrius Biosciences, Inc. is an immunotherapy company which specializes in cell process optimization, development and manufacturing. Its product candidate consists of NBS20, a targeted cancer immunotherapy product for the treatment of metastatic melanoma; NBS10, an ischemic repair product to preserve heart muscle function following an acute myocardial infarction and NBS03D, an immune modulation product for the treatment of diabetes which are in different clinical trials. Caladrius Biosciences, Inc., formerly known as NeoStem, Inc., is headquartered in New York.”
More notable recent Caladrius Biosciences Inc (NASDAQ:CLBS) news were published by: Marketwatch.com which released: “Caladrius Biosciences Inc.” on June 08, 2015, also Globenewswire.com with their article: “Caladrius Biosciences, Inc. Enters Into Agreements To Raise $25 Million in …” published on September 15, 2016, Quotes.Wsj.com published: “News Caladrius Biosciences Inc.CLBS” on June 09, 2015. More interesting news about Caladrius Biosciences Inc (NASDAQ:CLBS) were released by: Globenewswire.com and their article: “Caladrius Biosciences Receives FDA Fast Track Designation for CLBS03 to Treat …” published on July 28, 2016 as well as Globenewswire.com‘s news article titled: “Caladrius Biosciences, Inc. Finalizes Corporate Name Change From NeoStem, Inc.” with publication date: June 08, 2015.
CLBS Company Profile
Caladrius Biosciences, Inc., formerly NeoStem, Inc., incorporated on October 18, 1980, through its subsidiary, PCT, LLC, a Caladrius Company (PCT), provides development and manufacturing services to the cell therapy industry (which includes cell gene therapy). PCT specializes in cell and cell gene therapies. PCT offers development and manufacturing capabilities, quality systems, cell and tissue processing, logistics, storage and distribution and engineering solutions to clients with therapeutic candidates at all stages of development. The Company’s product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient’s own numerically and functionally enhanced Tregs. This therapy is based on a platform technology for immunomodulation.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.